drugset
drugset / Trial / NCT03245515

A Study of BMS-986195 in Healthy Male Subjects

NCT03245515 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effects BMS-986195 in healthy male subjects.

Timeline

Start
2017-08-15
Primary completion
2017-09-22
Completion
2017-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Branebrutinib Small molecule — Oral

Indications

rheumatoid arthritis